• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Actuate Therapeutics Inc.

    4/8/25 7:02:27 PM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACTU alert in real time by email
    DEFA14A 1 actuate_defa14a.htm ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

     

     

    Filed by the Registrant ☒                Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

    ☐ Preliminary Proxy Statement
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐ Definitive Proxy Statement
    ☒ Definitive Additional Materials
    ☐ Soliciting Material under §240.14a-12

     

    ACTUATE THERAPEUTICS, INC.

    (Name of registrant as specified in its charter)

     

    (Name of person(s) filing proxy statement, if other than the registrant)

     

    Payment of Filing Fee (Check the appropriate box):

    ☒ No fee required.
    ☐ Fee paid previously with preliminary materials.
    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

     

     

       

     

     

     

     

       

     

     

     

     

       

    Get the next $ACTU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACTU

    DatePrice TargetRatingAnalyst
    4/22/2025$21.00Buy
    Craig Hallum
    3/17/2025$20.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACTU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Thomson Todd S

      4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      5/23/25 4:37:19 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Sawhney Roger

      4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      5/23/25 4:05:33 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Keyes Jason A

      4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      5/23/25 4:05:28 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACTU
    SEC Filings

    See more
    • Actuate Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

      5/23/25 4:10:35 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Actuate Therapeutics Inc.

      S-8 - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

      5/15/25 4:12:31 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Actuate Therapeutics Inc.

      10-Q - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

      5/15/25 4:08:54 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACTU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bios Equity Cof, Lp bought $4,000,000 worth of shares (500,000 units at $8.00), exercised 37,951 in-the-money shares at a strike of $5.27, sold $224,991 worth of shares (24,999 units at $9.00) and converted options into 9,380,699 shares (SEC Form 4)

      4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      8/14/24 8:54:46 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Fletcher Aaron G.L. converted options into 9,380,699 shares, bought $4,000,000 worth of shares (500,000 units at $8.00), exercised 37,951 in-the-money shares at a strike of $5.27 and sold $224,991 worth of shares (24,999 units at $9.00) (SEC Form 4)

      4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      8/14/24 8:49:12 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Kreis Leslie W. converted options into 9,380,699 shares, bought $4,000,000 worth of shares (500,000 units at $8.00), exercised 37,951 in-the-money shares at a strike of $5.27 and sold $224,991 worth of shares (24,999 units at $9.00) (SEC Form 4)

      4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      8/14/24 8:44:04 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACTU
    Financials

    Live finance-specific insights

    See more

    $ACTU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

      HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential. Successfully dosed multiple pati

      3/27/25 4:01:00 PM ET
      $ACTU
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Actuate Therapeutics Inc.

      SC 13D - ACTUATE THERAPEUTICS, INC. (0001652935) (Subject)

      8/19/24 8:59:59 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACTU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

      Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1 months vs 7.2 months; log-rank p=0.01) in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving elraglusib/GnPRisk of death was reduced by 37% (HR=0.63) in patients treated with elraglusib/GnPData featured as an oral presentation at the ASCO Annual MeetingCompany plans to engage with FDA in the second half of 2025 to align on a path towards product registrationCompany to host KOL event today at 6:30 pm CDT to discuss 1801 Part 3B results CHICAGO and FORT WORTH, Texas, May 31, 2025 (GLOBE NEWSWIRE) -- Actua

      5/31/25 4:30:00 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

      Phase 2 (Actuate-1801 Part 3B) trial topline results meet primary endpoint of improved survival in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)Oral presentation at the American Society of Clinical Oncology (ASCO) annual meeting to highlight statistically significant improvement in median overall survival and 1-year survival rate in patients treated with the combination of elraglusib and gemcitabine/nab-paclitaxel (GnP) compared to GnP aloneCompany to host KOL event on May 31, 2025, to review data presented CHICAGO and FORT WORTH, Texas, May 22, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clin

      5/22/25 5:05:00 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting

      Fireside discussion to explore clinical impact of the topline Phase 2 data in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) to be presented at ASCOIn-person event and virtual webcast to be held on Saturday, May 31, 2025, at 6:30 pm CDT CHICAGO and FORT WORTH, Texas, May 07, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that it will host an in-person key opinion leader (KOL) event, during the 2025 American

      5/7/25 8:00:00 AM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACTU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Actuate Therapeutics with a new price target

      Craig Hallum initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $21.00

      4/22/25 8:00:39 AM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Actuate Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $20.00

      3/17/25 7:17:09 AM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care